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Abstract
Kinases are heavily pursued pharmaceutical targets because of their mechanistic role in many diseases. Small molecule
kinase inhibitors (SMKIs) are a compound class that includes marketed drugs and compounds in various stages of drug
development. While effective, many SMKIs have been associated with toxicity including chromosomal damage. Screening
for kinase-mediated toxicity as early as possible is crucial, as is a better understanding of how off-target kinase inhibition
may give rise to chromosomal damage. To that end, we employed a competitive binding assay and an analytical method to
predict the toxicity of SMKIs. Specifically, we developed a model based on the binding affinity of SMKIs to a panel of kinases
to predict whether a compound tests positive for chromosome damage. As training data, we used the binding affinity of
113 SMKIs against a representative subset of all kinases (290 kinases), yielding a 1136290 data matrix. Additionally, these
113 SMKIs were tested for genotoxicity in an in vitro micronucleus test (MNT). Among a variety of models from our
analytical toolbox, we selected using cross-validation a combination of feature selection and pattern recognition
techniques: Kolmogorov-Smirnov/T-test hybrid as a univariate filter, followed by Random Forests for feature selection and
Support Vector Machines (SVM) for pattern recognition. Feature selection identified 21 kinases predictive of MNT. Using the
corresponding binding affinities, the SVM could accurately predict MNT results with 85% accuracy (68% sensitivity, 91%
specificity). This indicates that kinase inhibition profiles are predictive of SMKI genotoxicity. While in vitro testing is required
for regulatory review, our analysis identified a fast and cost-efficient method for screening out compounds earlier in drug
development. Equally important, by identifying a panel of kinases predictive of genotoxicity, we provide medicinal chemists
a set of kinases to avoid when designing compounds, thereby providing a basis for rational drug design away from
genotoxicity.
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Introduction
Toxicity is a major cause of attrition in drug development.
While identifying liabilities and potential toxicity is difficult and
costly, safety issues can become markedly more complex when
kinases are the pharmaceutical target. Kinases regulate many basic
functions in normal cells. When their activity is altered, kinases can
be the mechanistic reason for a cell to acquire an abnormal
phenotype. In metabolic, oncologic, viral, cardiovascular and
inflammatory diseases, over 150 different kinases, of the over 500
known protein kinase family members, are considered putative
drug targets [1]. Marketed small molecule kinase inhibitors
(SMKIs) have suitably demonstrated the effectiveness of this
therapeutic approach for oncologic indications [2]. SMKIs
intended for non-oncologic diseases, however, are increasingly
represented in various stages of preclinical and clinical develop-
ment [1]. Most SMKIs exert their pharmacologic effect by
interacting with the ATP binding pocket [3], inhibiting the ability
of the kinase to phosphorylate the intended substrate, and blocking
downstream signal transduction. Because of the evolutionarily
conserved nature of the ATP binding pocket, a SMKI intended to
inhibit a particular kinase may potently inhibit dozens of other
kinase members across the human kinome [4]. Off-target kinases
can be a potential safety liability of this therapeutic class and
hinder drug development. The mechanisms by which different
toxicities arise as a result of off-target inhibition are not well
characterized. Sutent, a highly non-selective inhibitor of multiple
tyrosine kinases and Gleevec, a relatively selective Bcr-Abl
inhibitor, both increase the risk of cardiotoxicty [5–7], though
additional, less publicized toxicities, are also common for SMKIs.
Kinases are key regulators of mitosis, as they are intricately
involved with precise signaling and the coordination needed for
proper replication and segregation of chromosomes into daughter
cells [8–10]. While kinases may be targeted for their role in
pathways associated with a disease of interest, inhibition of kinases
may also disrupt normal cellular processes. A frequently observed
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an assay of DNA integrity, which likely occurs as the result of
inhibiting kinases involved in mitosis or chromosomal segregation.
The micronucleus test (MNT) is widely regarded as a sensitive
assay for genetic toxicity as it is a means to detect either pieces
and/or whole chromosomes that appear as a micronucleus in the
daughter cell following chemical exposure [11,12]. A positive
result in this assay can hamper or halt drug development, as it is a
biomarker of chromosomal damage, which is a hallmark of cancer
[13–15]. Thus, human exposure to aneugens or clastogens should
be attenuated, or avoided altogether, when possible. A small
number of kinases, such as the polo-like and aurora kinases [16–
19], are known to associate with chromosomal damage, however
the genotoxic potential associated with inhibiting the majority of
the kinome is largely unknown.
MNT results can be considered a surrogate, and sometimes
predictive endpoint for carcinogenicity. This study models this
endpoint because of its correlation with genotoxicity and the
availability of a set of training compounds that have been screened
with this assay. Although regulatory agencies require such an in
vitro assay prior to moving forward with preclinical development,
there are advantages to modeling this assay in silico. Namely,
because of the low-throughput nature of the assay, the drug
discovery process would benefit from a cheaper, faster screen that
could assist in reducing the number of leads that typically fail at
later stages, as well as help design compounds with fewer safety
liabilities. Since all promising SMKIs at Roche are tested in kinase
inhibition assays, these data present the opportunity to explore
possible correlations between SMKI kinase selectivity and the
potential to cause chromosomal damage.
The objective of this study was to identify kinases that correlate
with chromosomal damage when inhibited. At Roche, we aimed
to use these findings as a set of kinases that medicinal chemists
should avoid when designing compounds, so as to avoid positive
MNT results, thereby reducing attrition rates. By using machine
learning methods on data that were already available from early
kinase-based high-throughput screens, we were able to identify
such a set of kinases and develop a fast and efficient model for
predicting whether a compound will test positive for genotoxicity.
Besides its novel utility in the drug discovery pipeline, the model
also sheds light on the biological mechanisms of genotoxicity, and
allows us to create hypotheses for further studies.
Results
Dataset
The 113 SMKIs were chosen to represent a diversity of
compound properties and structural moieties. Figure 1 shows a
Principal Components Analysis (PCA) plot of the training
compounds, in color, overlaid on top of a plot of all Roche
compounds that have been screened with Ambit Biosciences (San
Diego, CA) KINOMEscan assay of 317 kinases. The PCA was
based on structural fingerprints, a representation of the molecular
structure of each compound. This method of analysis is a means
for reducing dimensionality to best explain variability in the data.
Figure 1 shows that structures of the 113 compounds are highly
variable and sample the chemical space of the entire Roche SMKI
library well. With a diverse training set, chances of redundancy are
reduced and the model is likely to be more robust to future
predictions.
During dataset preprocessing, 27 mutant kinases were removed
from the initial panel of 317 kinases as their inclusion and potential
selection would be difficult to interpret from biological and
mechanistic standpoints. This yielded a panel of 290 kinases,
identified in Table S1. An additional 5 uninformative kinases were
removed from the panel as their percent inhibition values did not
vary significantly across positive and negative SMKIs. Thus,
preprocessing yielded a data matrix of 1136285 for machine
learning analysis. A heatmap of the full dataset prior to
preprocessing can be found in Figure S1. Of the 113 compounds,
30 and 83 SMKIs were classified as MNT positive and negative,
respectively.
Model methods
In the first phase of the analysis, several models were generated,
each based on 1065-fold cross validation for a particular
combination of feature selection methods and a binary classifier.
In this phase, the best performing feature selection methods were a
Kolmogorov-Smirnov/T-test hybrid algorithm, followed by Ran-
dom Forests. The most informative features were then input into a
non-linear Support Vector Machines (SVM) classifier.
The Kolmogorov-Smirnov/T-test algorithm is a univariate
filter method used to filter features based on their p-value. Briefly,
for each feature, the distribution of percent inhibition values was
assessed. If normal, a t-test was performed to yield a p-value.
Otherwise, a Kolmogorov-Smirnov test was run. Features were
ranked by p-value, and the top 100 features or less that met the
0.05 p-value cutoff were retained for further analysis. The 100 or
less features from the first method were then input into Random
Forests [20], a multivariate feature selection method based on
decision trees. In this phase of the analysis, Random Forests was
used to select 10 features for input into the binary classifier.
SVMs are widely used in bioinformatics and other applications
of supervised learning. SVMs are used to find a hyperplane that
maximizes the margin between the two classes of compounds in n-
dimensional space, where in this analysis, n corresponds to the
number of features selected using Random Forests. Initial
classification was performed using a nonlinear Radial Basis
Function (RBF) kernel, with a cost of 1 and a gamma of 0.
After selecting the model methods, the second phase of the
analysis involved optimizing the model parameters. The 10 splits
of 5-fold cross validation were then used with the model methods
Author Summary
Small molecule kinase inhibitors (SMKIs) are a class of
chemicals that have successfully been used for the
treatment of a number of oncological diseases that are
now being pursued by the pharmaceutical industry for
inflammatory diseases, such as rheumatoid arthritis. SMKIs
are generally designed to specifically inhibit one kinase,
but this is challenging due to the structural similarity of the
ATP binding pocket amongst different members of the
kinase family. The inability to selectively inhibit just one
kinase can be problematic, as kinases play key roles in a
number of cellular processes. Thus the unwanted inhibi-
tion of additional kinases can lead to undesirable toxicities
that may halt drug development. One type of toxicity
often observed with this class of compounds is damage to
chromosomes, which can occur when kinases involved
with cell cycle progression or chromosome dynamics are
inhibited. Here we demonstrate that mathematical mod-
eling can be used to identify kinases that correlate with
chromosome damage, information which can assist
medicinal chemists in avoiding certain kinases when
synthesizing new chemicals. Generation of this type of
information is one of the first steps in beginning to reduce
toxicity-based attrition for this class of compounds.
Predicting Kinase-Mediated Chromosome Damage
PLoS Computational Biology | www.ploscompbiol.org 2 July 2009 | Volume 5 | Issue 7 | e1000446to sweep over the number of features from 2 to 50. Optimal
performance was achieved with 45 features. To avoid overfitting
and make the model generalizable to future compounds, we
selected the minimum number of features whose model yielded an
accuracy within one standard deviation of the performance
obtained when using 45 features. Thus we selected 21 as the
number of features to select for the final model.
Using the full dataset, SVM cost and gamma parameters were
then tuned. Briefly, gamma is a parameter that affects the size of
the hyperplane in an SVM, while cost is a penalizing measure for
having a sample on the wrong side of the hyperplane. Tuning
yielded an optimal cost of 2 and a gamma of 2
24 using an RBF
kernel.
Model performance
Final model performance was based on a re-split of the data into
50 random splits of 10-fold cross validation. Using the final model
methods and optimized parameters, the 500 iterations yielded a
cross-validated estimate with an overall classification accuracy of
85% (standard deviation 1.8%), sensitivity of 68% (standard
deviation 5.0%), and a specificity of 91% (standard deviation
2.0%). A receiver operating characteristic (ROC) curve of the
cross-validated and overall mean performance is shown in Figure 2.
Model kinases
From the 50 splits of 10-fold cross validation used to assess final
model performance, the frequency that each feature was selected
as significant in Random Forests was tabulated. The features were
then ranked, and the top 21 most frequently-selected kinases were
chosen as the model kinase profile. The 21 model kinases are
CAMK1 (NP_003647.1), CAMK2A (NP_741960.1), CAMK2D
(AAD20442.1), DYRK1B (NP_004705.1), MAPK15
(NP_620590.2), PCTK1 (NP_006192.1), PCTK2 (CAA47004.1),
PCTK3 (NP_002587.2), PFTK1 (NP_036527.1), CDK2
(NP_001789.2), CDK3 (NP_001249.1), CDK5 (NP_004926.1),
GSK3A (NP_063937.2), CLK2 (NP_003984.2), MELK
(NP_055606.1), BRSK2 (NP_003948.2), STK3 (NP_006272.2),
MYLK (NP_444254.3), FLT3 (NP_004110.2), EIF2AK2
(NP_002750.1), and PRKAA2 (NP_006243.2). Table 1 lists the
21 kinases and the frequency that each was selected as significant
in this phase of the analysis. A heatmap of the percent inhibition
values against these 21 kinases is shown in Figure 3 and
Figure 1. Principal component analysis (PCA) assessing the structural diversity of the 113 SMKIs. Positive and negative micronucleus
results are marked in red and green, respectively. Roche SMKIs that have not been tested in the MNT are colored light grey. Compounds selected for
this study cover a broad range of chemical space within the Roche SMKIs and reduce redundancy within the test set.
doi:10.1371/journal.pcbi.1000446.g001
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with MNT positive results.
Assessment of kinases
To verify the statistical significance of the kinases, a dropout
experiment was run using the preprocessed dataset, minus the 21
model kinases. Using the same methods and 50 splits of 10-fold
cross validation, the performance of the modified dataset (113
compounds6264 kinases) was assessed. The dropout model
yielded an accuracy of 78% (standard deviation 2.4%), sensitivity
of 54% (standard deviation 5.9%), and specificity of 87% (standard
deviation 2.0%). All performance metrics for the dropout model
yielded values at least one standard deviation worse than the
original model, demonstrating the significance of the 21 identified
kinases. Additionally, to address multiple comparisons concerns,
the q-values were calculated for all model kinases. The FDR, or
False Discovery Rate [21], estimates the expected proportion of
false positives in the data, and in this case, was based on the p-
values derived from the Kolmogorov-Smirnov/T-test algorithm
on all 290 kinases across all 113 compounds. Q-values, which
represent the minimum FDR at which each feature may be called
significant, were then calculated using the ‘‘qvalue’’ package in R
[22]. At an FDR of 0.05, 73 kinases of 290 may be called
significant, including all model kinases. At an FDR of 0.01, 21
kinases may be called significant, although this includes only 10 of
the model kinases. Q-values for all model kinases are listed in
Table 1. This result is expected since the kinases were selected
based on both the filtering of feature selection one and the
multivariate criterion of FS2.
Figure 2. Receiver operating characteristic (ROC) curves for
cross-validated assessment of final model performance. Shown
are ROC curves for each of the 50 splits of 10-fold cross validation (grey)
and overall average ROC curve (red), based on SVM predictions. AUC
performance ranged from 0.81 to 0.89 across the 50 splits with an
average AUC of 0.84+/20.021.
doi:10.1371/journal.pcbi.1000446.g002
Table 1. 21 kinases selected by mathematical modeling.
Entrez Gene Symbol Entrez Gene Accession Incidence of Selection % Selected q-value
CAMK2A NP_741960.1 500 100 1.82
204
CAMK2D AAD20442.1 500 100 6.44
203
DYRK1B NP_004705.1 500 100 4.31
205
MAPK15 NP_620590.2 500 100 4.81
207
PCTK2 CAA47004.1 499 99.8 2.00
205
PFTK1 NP_036527.1 498 99.6 1.27
203
PCTK1 NP_006192.1 492 98.4 2.00
205
PCTK3 NP_002587.2 492 98.4 4.46
203
CDK2 NP_001789.2 482 96.4 9.85
205
GSK3A NP_063937.2 447 89.4 6.80
206
CDK3 NP_001249.1 438 87.6 8.78
203
CLK2 NP_003984.2 431 86.2 2.24
205
MELK NP_055606.1 377 75.4 1.02
203
BRSK2 NP_003948.2 367 73.4 1.93
202
CAMK1 NP_003647.1 300 60.0 1.37
202
STK3 NP_006272.2 282 56.4 1.31
203
MYLK NP_444254.3 263 52.6 4.20
202
CDK5 NP_004926.1 254 50.8 6.59
203
FLT3 NP_004110.2 241 48.2 4.31
205
EIF2AK2 NP_002750.1 217 43.4 4.84
202
PRKAA2 NP_006243.2 214 42.8 3.32
203
21 model kinases identified by frequency of selection in final phase of model assessment. Incidence of selection and percent selected values were based on 50 splits of
10-fold cross validation in the final phase of assessing model performance. Q-values were calculated from p-values from the Kolmogorov-Smirnov/T-test algorithm in
the first phase of feature selection, as described in Results – Model methods.
doi:10.1371/journal.pcbi.1000446.t001
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literature was performed to find studies that might prove or
suggest a mechanistic link between the model kinases and mitosis
or genetic toxicological damage. The majority of the kinases
selected by this analysis (12/21) are members of the CMGC kinase
family which is known to be involved with the control of cell
proliferation. The cyclin dependent kinases (CDKs) are a family of
CMGC kinases that have been associated with mitosis and the cell
cycle, and generally speaking, bind with cyclins during the various
phases of mitosis. While the three CDKs (2,3, & 5) in the model all
appear to have inhibition that is specific to the MNT positive
compounds (Figure 3) and are members of a family of kinases
known to have roles in mitosis, only CDK2 has supporting
literature making it biologically relevant to chromosomal damage.
Little is known about the cellular function of the other CMGC
members of the CDK kinase family, such as PFTAIRE (PFTK1)
and PCTAIREs 1–3 (PCTKs). From this family, PFTK1 is the
only kinase with literature supporting its biological relevance.
PFTK1 is a CDK2-related protein kinase which has been reported
to phosphorylate the tumor suppressor Rb and interact with p21,
suggesting that PFTK1 is involved in cell cycle regulation [23].
The activity of PCTK1 is cell-cycle dependent and displays a peak
in the S and G2 phases [24].
Selected kinases in the second largest group (7/21) are members of
the calmodulin mediated kinase (CAMK) family, of which only
MYLK has been reported to interact with chromosomes. The
smooth muscle myosin light chain kinase (smMLCK or MYLK),
which facilitates the movement of anaphase chromosomes through its
Figure 3. Heat map of kinase inhibition of the 21 kinases selected by mathematical modeling. The 113 SMKIs used in the analysis are
classified as micronucleus positive (red, on the bottom) or negative (green) and are located along the y-axis on the right side of the figure. The 21
kinases are located along the x-axis. If inhibited below 50%, the corresponding area is marked black, whereas kinase inhibition between 50–100% is
represented by a gradient of dark to bright red.
doi:10.1371/journal.pcbi.1000446.g003
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family with reported association with chromosome kinetics or the cell
cycle, which has also been reported to induce spindle disruptions
leading to metaphase arrest and chromosome defects [26].
Discussion
We applied a statistical modeling framework to identify a panel
of kinases that are predictive of a positive micronucleus test result,
a sign of potential chromosomal damage. To our knowledge, this
approach is the first application of a computational method to
correlate high-throughput kinase screening results with a toxico-
logical endpoint. The described mathematical model is capable of
predicting MNT results correctly 85% of the time based solely on
compound inhibition profiles against 21 kinases. The model
presented herein indicates that chromosomal damage induced by
many of the tested small molecule kinase inhibitors (SMKIs)
correlates to their kinase inhibition profiles and that this
knowledge can be used to design compounds with improved
safety profiles at earlier stages of drug discovery. While the 21
kinases identified in this analysis are statistically significant for our
given dataset, our understanding of their mechanistic roles in
chromosomal segregation and mitosis is still in its early stages. A
heatmap of the inhibition values against these 21 kinases (Figure 3)
displays a general pattern: SMKIs that are MNT negative tend to
inhibit the 21 kinases much less frequently than the SMKIs that
are MNT positive.
While some kinases selected by the model have a known
function in cell cycle or chromosomal segregation, others have an
unrelated or unknown role. The majority of the kinases chosen are
members of the CMGC kinase family, which is known to be
involved with the control of cell proliferation. While the role of
CDK2 is well-documented, the biological relevance of CDK3 and
CDK5 is less clear. CDK3 was identified to complex with cyclin C
and phosphorlyate the retinoblastoma tumor suppressor protein
[27] and mediates the G1-S transition of the cell cycle [28].
However, there are no reports of its involvement with chromo-
somal segregation. CDK5 has been described as an unusual
member of the CDK family because it has little known role in
cellular proliferation and is activated by non-cyclin proteins [29].
The three CDKs (2,3, & 5) chosen all appear to have inhibition
that is specific to the MNT positive compounds (Figure 3), and are
members of a family of kinases known to have roles in mitosis, thus
it is plausible that their inhibition could cause aberrant mitosis and
errors in chromosomal segregation. Other model kinases selected
from the CMGC family are not known to have a clear role in
chromosomal segregation. Collectively, it appears that inhibition
of the PCTK kinases (PCTAIREs 1–3) strongly associates with
chromosomal damage though this information has not been
previously published. The family of MAPKs is well-known to have
a fundamental role in mitosis and cell cycle control [30], and are
involved with chromosome damage and micronucleus formation
[31], though this is the first report placing MAPK15 in such a role.
Glycogen synthase kinase 3 alpha (GSK3a) has been reported to
be involved with chromosome alignment and cytokinesis [32–35],
thus its selection by mathematical modeling is not unanticipated.
However, GSK3a is one of the more promiscuous kinases selected
in the mathematical model, with a large number of micronucleus
negative compounds also inhibiting the kinase above 80% at the
10 mM concentration (Figure 3). These data contrast with reported
literature, as they suggest that combinations of kinase inhibition,
rather than just GSKa alone, may be required for chromosome
damage. Model kinases in the calmodulin mediated kinase
(CAMK) family were the most specific with regard to their
inhibition of micronucleus positive compounds (Figure 3) and were
repeatedly chosen by the model, yet the majority, including
CAMK1a, CAMK2a and 2d, MELK, BRSK2, and PRKAA2, do
not have any reported function involving mitotic chromosome
dynamics. The two remaining kinases are FLT3 and MST1,
neither of which have any known role in either chromosomal
segregation or mitosis. FLT3 has been reported to associate with
acute lyphoblastic leukemia [36] and chromosomal instability in
the form of hyperdiploid aneuploidy observed in the same disease
[37], but its inhibition has not been linked to the missegregation of
chromosomes. MST1, also known as STK3, has been identified to
be a substrate of caspases and play a role in apoptosis [38].
Besides lack of validation of the mechanistic relevance of some
model kinases, additional experimental limitations are that kinase-
independent mechanisms of micronucleus formation exist while
others are based upon analysis parameters. In any analysis, the
robustness of modeling complex endpoints is limited by the
training dataset. Care was taken in selecting which compounds to
include and were chosen by judiciously sampling our internal
kinase inhibitor library for SMKIs representative of broad
scaffolds and designed for a variety of kinase targets. Nevertheless,
data were limited to past and current kinase projects at Roche and
may not reflect future efforts. Another potential concern with this
approach is that not all kinases are available in the Ambit
competition binding assay. At the time of the analysis, only 290 of
the 518 protein kinases were tested. While the 290 kinases account
for a large portion of the kinome and do not appear to miss large
branches of the kinome tree (data not shown), current panels are
more comprehensive and will likely be more complete in the
future. In addition to the inherent limitations of the training set,
the modeling approach does not necessarily identify all kinases that
are highly predictive of chromosome damage. As an example,
several kinases were statistically significant in FS1 but were not
selected by the FS methods. This is a challenge often observed
while analyzing large data sets [39–41]: features that correlate
individually with the endpoint are not chosen because they may be
correlated with other features that are more highly correlated with
the endpoint, and thus these features become redundant. Said
differently, it is often the case that there is more than one set of
features that is highly predictive of the endpoint. Such observa-
tions have been made frequently in other areas of biological
research where the number of features outnumbers the sample
number, e.g. microarray studies [39–41].
Despite limitations, the strengths of this method lie in its utility.
At Roche and other pharmaceutical companies, SMKIs are
designed to inhibit a kinase that has a known role in the pathway
or disease of concern. While hundreds of compounds may be
developed that strongly bind to their target kinase, it is not often
clear whether inhibiting other, non-targeted kinases will affect the
success of the compound in further stages of the pipeline,
especially in toxicological studies, where many compounds often
fail. In the process of building the model, we found that
promiscuous SMKIs often tested positive for micronuclei forma-
tion (Figure S1), and this was greatly enriched through model
development (Figure 3). While general promiscuity may be a
relatively good marker for determining the outcome of a
micronucleus assay, there are examples where it isn’t (Figure
S1), suggesting that specific inhibition of particular kinases is of
relevance. Providing information to medicinal chemists early in
the lead identification/optimization process, beyond just general
guidance of promiscuity, is critical to the success of such a strategy,
as it provides direction for development as well as compound
prioritization for additional development. Knowledge of these 21
kinases within Roche has been of assistance in designing SMKIs
Predicting Kinase-Mediated Chromosome Damage
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compound class.
While the framework presented here provides a robust method
for identifying kinases correlated to genotoxicity, causality must be
addressed by other means, along with concerns about indirect
mechanisms of action and kinases not included in the dataset.
There are several kinases that are not solely inhibited by MNT
positive compounds, including CLK2, FLT3, GSK3a, MAPK15,
PCTK1, and EIF2AK2. This raises the question of whether their
inhibition specifically causes the micronucleus formation or if their
inhibition requires the inhibition of other kinases for the induction
of chromosome damage. Because there is high sequence homology
amongst kinases in the ATP binding pocket, it is possible that some
of the selected kinases do not cause chromosomal damage, but
instead are correlated with the inhibition of others that do.
Alternatively, there a number of MNT positive compounds that do
not inhibit any of the kinases chosen in the model. Possible
explanations include: first, a number of mechanisms independent
of kinase inhibition can influence mitotic chromosome dynamics
and second, kinases, which have not been screened in this study,
may influence the outcome of the micronucleus result.
Development of SMKIs that carry a genotoxic liability can
occur, though the generation of additional data demonstrating
that the mechanism of action occurs in a non-DNA reactive,
threshold-observable manner, is often necessary to appease
regulatory agencies. These additional developmental complexities
are best avoided, as they are expensive, time consuming, and no
guarantee exists that attrition due to chromosomal damage will be
avoided. Thus, many companies prefer to spend time and
resources during lead optimization to identify compounds free of
such liabilities, rather than risk failure due to later-stage attrition.
The use of mathematical modeling to better understand what
underlies such toxicities is one of the first steps in designing drugs
free of these particular liabilities.
Additional studies can shed light on the underlying pathways
possibly connecting the model kinases, as it is clear that all are
involved in some larger biological network and should not be
considered as independent features. Experimental studies can help
to confirm possible connections. As a basis for such future
investigations, our methodology provides a starting point for
biological hypothesis generation, in addition to its utility as a
computational model for predicting genotoxicity.
Materials and Methods
Compounds
The 113 compounds used in this project were synthesized
internally or purchased from Sigma Chemical company (St. Louis,
MO). The structural diversity of the 113 compound training set
was assessed by representing each compound with Extended
Connectivity Fingerprints (ECFP) in Pipeline Pilot 6.0 [42], a
molecular characterization of compounds as a 2-dimensional
fingerprint. ECFP for each compound was used as input for
principal components analysis (PCA), as shown in Figure 1.
Kinase inhibition
All 113 compounds were sent to Ambit Biosciences (San Diego,
CA) for kinase selectivity analysis against 317 kinases using
KINOMEscan assays. These 317 kinases cover a large and diverse
portion of the human kinome. For each kinase in this high-
throughput competition binding screen, ligand-bound kinase
quantities are measured in the presence and absence of the
compound. Input values for this project are reported in terms of
percent inhibition (%) for each compound against each of the 317
kinases. These measurements provide a means for identifying on-
target and off-target kinases, as well as for quantifying the
selectivity or promiscuity of an SMKI. This is performed in a cell
free binding assay which is used as a surrogate for cellular kinase
inhibition, which can be influenced by physical-chemical proper-
ties (solubility and permeability) that may impact intracellular
concentrations and kinase inhibition.
In vitro micronucleus test
The in vitro micronucleus assay was conducted according to a
previously published protocol [43]. Briefly, the established
permanent mouse lymphoma cell line L5178Y tk
+/2 (ATCC
CRL 9518) growing in suspension was obtained from Covance
Laboratories Ltd. (Harrogate, UK). The top dose for evaluation
was generally selected to observe acceptable toxicity (decrease of
the relative cell count (RCC) below 50%) or clear signs of
precipitation in the aqueous medium. Micronucleus results
obtained when the RCC falls below 40% are not interpreted as
this exceeds the cytotoxicity cut-off. Soluble and non-toxic
compounds are evaluated up to a maximal dose level of
5000 mg/mL or 10 mM whichever is lower. The cell cultures
were exposed to the test compound for 24 h and harvested either
immediately or following a 24 h recovery period in case of cell
cycle arrest. For assessment of cytotoxicity cell numbers are scored
at harvest with the use of a Coulter Counter and relative cell
counts (RCC, as % negative control) were calculated (population
doublings and cell morphology were assessed in parallel). 1000
cells per dose were scored with a magnification of 10006 and
micronuclei were evaluated according to previously described
criteria [44]. A compound is considered to induce a significant
level of micronuclei, and thus yield a positive MNT result, if one or
more concentrations show at least a 2% frequency of micro-
nucleated cells in either of the two testing regimens (generally
corresponding to a 2.5 fold increase over historical controls).
Methylmethanesulfonate (15 mg/ml) is used as a micronucleus
positive control.
MNT assay results were ultimately considered binary, with a
positive result corresponding to toxicity and a negative result to
non-toxicity. While some compounds were easily classified, others
required reclassification because of experimental parameters.
Because Ambit data was measured at a 10 mM concentration for
all SMKIs, positive micronucleus results that occurred above this
10 mM cutoff could be due to kinase inhibition that would not be
reflected in the kinase inhibition assay results. Thus, to better
correlate the kinase inhibition to micronucleus positive results,
compounds identified to be micronucleus positive above this
threshold were reclassified as negative.
Dataset
The study was based on a training set of 113 internal SMKIs.
To make the model generalizable to the prediction of future
compounds, a large and structurally dissimilar group of SMKIs
was selected. The training set compounds were chosen to
represent a diversity of molecular structures, physicochemical
properties, and kinase targets. Each compound was assessed for
chromosomal damage, a sign of potential toxicity, using an in vitro
micronucleus test. Additionally, each compound was screened in a
competition binding assay to quantify inhibition of 317 kinases.
Preprocessing was performed prior to employing machine
learning methods. From the 317 kinase panel, mutant kinases were
removed from the dataset as their mechanistic function would be
difficult to interpret. Additional kinases were removed because
their percent inhibition level, usually less than 50% at 10 uM, did
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when separating positive from negative MNT results.
Model-building framework
When building a model to predict a binary endpoint, best
practices for machine learning recommend using feature selection
methods to reduce dimensionality of the data, followed by input
into a pattern recognition method. From observation, we have
seen that while a selection of certain methods performs well with a
given dataset, others methods do not. Similarly, while there are
many instances of machine learning methods that perform well,
their performance results are not always reproducible with other
datasets. In this analysis we present a framework that involves
sweeping over variety of methods, which allows the choice of
methods to be driven by the data rather than investigator
preference, and selecting methods and method parameter based
on top-performing results. An overview of the framework is given
in Figure 4. Implementation details of the framework, such as
choice of programming language and which methods to include,
are left to the investigator. This analysis was performed in R
version 2.6.2 [45], based on the number of machine learning
packages readily available.
Generation of models
The first phase of the analysis aimed to identify the machine
learning methods to be used in the model (Figure 4a). We started
by creating 10 random splits of 5-fold stratified cross validation.
Briefly, each split randomly grouped the 113 SMKIs into 5
subsets, or folds. Each fold was stratified, meaning that the
proportion of MNT positive compounds to MNT negative
compounds in each fold roughly reflected that of the full dataset.
For each of the k folds, k-1 subsets were used as the training set to
build the model, while the remaining subset was used as the test set
to estimate performance.
For each fold within each split of data, a combination of two
feature selection (FS) methods were run, followed by a binary
Figure 4. Framework for building, optimizing, and assessing mathematical model. The computational framework for identifying a model
first starts by sweeping through combinations of univariate and multivariate feature selection methods, followed by a pattern recognition method.
The best performing combination of methods is selected for the final model (A). In the optimization phases, the optimal number of features to use in
the final model (B) and tuned parameters of the pattern recognition method (C) are identified. In the final phase of the framework (D), the model
methods from A and the optimized parameters from B and C are used to identify the final model features and assess final model performance.
doi:10.1371/journal.pcbi.1000446.g004
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features, are likely to correlate most with MNT result. Feature
selection methods were separated into two groups: univariate filter
methods capable of handling larger input data (FS1), and more
computationally-intensive multivariate methods (FS2). FS1 meth-
ods consider features independently and are thus less likely to
overfit to the given dataset. Such methods include a Kolmogorov-
Smirnov/T-test filter, single train error [46], and ReliefF [47].
However, since the FS1 methods do not address redundancy of
features, multivariate approaches were employed in FS2 to
consider correlation among a given subset of features. FS2
methods included random forests [20], genetic algorithm [48],
simulated annealing [48], Gram-Schmidt Orthogonalization [49],
and RFE-SVM [50]. The inhibition values against the features
chosen in FS2 were then used as input into a pattern recognition
(PR) method which predicted a positive or negative result.
Classifiers implemented in the PR phase included support vector
machines [51], random forests [20], linear discriminant analysis
[52], k-nearest neighbors [53], partial least squares [54], and
principal components analysis [45]. This analysis swept over
several combinations of FS1, FS2, and PR methods, although the
analysis may include any method that can be implemented within
the computational framework.
For each combination of FS1, FS2, and PR, model performance
was estimated using 10 splits of 5-fold cross validation. The FS1,
FS2, and PR method combination that yielded the greatest
accuracy was chosen for model optimization in the next phase of
the analysis.
Model optimization
Once the model methods were selected, the second phase of the
analysis aimed to identify the optimal model parameters, namely
the number of features to be used in the final model kinase profile,
as well as hyperparameters for the binary classifier (Figure 4b and
4c). For the same 10 splits of 5-fold cross validation, FS1, FS2, and
PR methods were fixed. First, for each trial of 1065-fold cross
validation, the first part of this phase entailed sweeping over a
different number of features to be selected in FS2. This number
would ultimately dictate the number of kinases to be used in the
final model profile. Similar to selecting model methods in the
previous phase, the model number of features was chosen based on
which number yielded the lowest error rate. In order to avoid
overfitting, the lowest number of features with a mean accuracy
within one standard deviation of the optimal number of features’
accuracy was chosen for the final model.
The second part of this model optimization involved tuning of
the hyperparameters for the optimal PR method. Tuning
methodology will be dictated by the optimal PR method selected
in the first phase of the model. Our analysis yielded Support
Vector Machines (SVM) as the optimal PR method. Thus in this
optimization phase of the analysis, we used the full dataset and
swept over cost, gamma, and kernel function to identify the
optimal SVM hyperparameters to use in the final model. Another
example hyperparameter is the number of neighbors k used in a
vote-based classifier such as k-nearest neighbors. Specific param-
eters depend on which PR method was selected in the previous
phase of the analysis.
Model assessment
The final phase of the analysis aimed to estimate the
performance of the final model and identify the model kinase
profile (Figure 4d). Ideally, an external set of compounds would be
used to validate the model after model optimization. Because such
data were not available at the time, model performance was
assessed by re-splitting the original dataset into 50 splits of 10-fold
cross validation. This number of iterations is much greater than
the 10 splits of 5-fold cross validation used when building and
tuning the model and provides for a more accurate performance
estimate. While more iterations of the model were run,
computational costs were manageable as model methods and
parameters were already pre-selected. For each fold in each split,
the optimal FS1 and FS2 methods selected in the model-
generating phase of the analysis were run. The N most informative
features were chosen in FS2 for each fold, with N being selected
during model optimization. For each fold, the N selected features
were then inputted into the optimal PR method with the
hyperparameters that were chosen in the model optimization
phase.
Final model performance was estimated by calculating mean
accuracy, sensitivity, and specificity over all 500 iterations (50 splits
of 10-fold). The kinase profile for the final model was then
calculated based on frequency of selection during FS2. After
tabulating how many times each kinase was selected in the 500
runs, the top N were chosen as the final model set, as they are
often selected as informative when separating class labels.
The statistical relevance of kinases in the model profile was
verified by performing a dropout experiment. From the 290
kinases, the N final model kinases were removed. The final phase
of assessing model performance was then run using 50 splits of 10-
fold cross validation with an input data matrix of 113
compounds6(290-N) kinases. Performance results of the dropout
experiment were then compared to that of the original model.
Additionally, q-values for each of the final model kinases were
calculated to assess feature significance based on minimum false
discovery rates. The biological relevance of kinases in the model
profile was then verified by reviewing literature.
Supporting Information
Table S1 List of kinases used for analysis.
Found at: doi:10.1371/journal.pcbi.1000446.s001 (0.44 MB
DOC)
Figure S1 Kinase inhibition heat map of the 113 small molecule
kinase inhibitors assayed for micronuclei and the 290 Ambit panel.
Found at: doi:10.1371/journal.pcbi.1000446.s002 (0.93 MB TIF)
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